コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 aphy-computed tomography (PET/CT) with (18)F-fluorodeoxyglucose.
2 pping of the glucose analog 2-deoxy-2-[(18)F]fluorodeoxyglucose.
3 t of mice at much higher contrast than (18)F-fluorodeoxyglucose, (11)C-methionine and pH-insensitive
4 e imaged by direct positron imaging of (18)F-fluorodeoxyglucose ((18)F-FDG) and fluorescence microsco
5 response [PR]), which was assessed by (18)F-fluorodeoxyglucose ((18)F-FDG) PET at the end of the tre
8 raphy (PET), 0.89 and 0.74 for (18)F-labeled fluorodeoxyglucose ((18)F-FDG) PET, 0.64 and 0.83 for si
10 assesses brain amyloid deposition, and (18)F-fluorodeoxyglucose ((18)F-FDG) PET, which assesses gluco
13 e recommendations for the optimal use of (18)fluorodeoxyglucose ((18)F-FDG) PET/CT in patients with m
14 on-weighted MRI with standard clinical (18)F-fluorodeoxyglucose ((18)F-FDG) PET/CT scans in children
15 nd cellular inflammation, reflected by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomogra
16 the cellular inflammatory response by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomogra
17 al viability compared to gold-standard (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomogra
20 terize vascular inflammation by hybrid (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomogra
24 mportant characteristics of incidental (18)F-fluorodeoxyglucose ([18 F]FDG) positron emission tomogra
25 We used PET/CT imaging with [(18)F]-labeled fluorodeoxyglucose ([(18)F]-FDG) in monkeys after monkey
26 aging of the primary breast tumor with (18)F-fluorodeoxyglucose ([(18)F]FDG) PET may assist in predic
27 ed in a subset of monkeys (n=8) using [(18)F]fluorodeoxyglucose ([(18)F]FDG) with positron emission t
28 in a multiparametric profile based on [(18)F]Fluorodeoxyglucose ([(18)F]FDG)-PET and DW-MRI, which id
30 y was designed to evaluate the role of (18)F-fluorodeoxyglucose (18FDG) positron emission tomography/
31 ognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomography
32 and computed tomographic imaging with (18)F-fluorodeoxyglucose, a glucose analog, but the underlying
33 versus 1.30 [1.22-1.49]; P<0.001) and (18)F-Fluorodeoxyglucose activity (tissue-to-background ratio,
38 isease (age range: 50-90) were scanned using fluorodeoxyglucose and Pittsburgh compound B positron em
39 .7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose-avid IMLN, with a median standardized
41 ce between bSUVmax of the most and least 18F-fluorodeoxyglucose-avid lymphoma sites) was 8.0 (range,
42 for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice a
44 an dual-echo GRE imaging for nodules without fluorodeoxyglucose avidity (68% vs 22%, respectively; P
45 to normal tissues has long been utilized in fluorodeoxyglucose-based positron emission tomography (F
46 with positron emission tomography and [F-18]fluorodeoxyglucose before and after 6 weeks of treatment
47 f colon tumors and colonic uptake of [(18)F]-fluorodeoxyglucose by positron emission tomography in Hd
48 ht to assess whether (18)F-fluoride or (18)F-fluorodeoxyglucose can identify culprit and high-risk ca
50 itron emission tomography study with [(18)F]-fluorodeoxyglucose during euglycemic hyperinsulinemia.
51 oroparietal glucose metabolism determined by fluorodeoxyglucose F 18 [FDG]-labeled positron emission
52 aphy and brain imaging were unchanged, and a fluorodeoxyglucose F 18 positron emission tomographic sc
54 test this hypothesis, we evaluated F-labeled fluorodeoxyglucose ([F]FDG) and N-labeled ammonia ([N]NH
55 }]2) PET/computed tomographic (CT) and (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose
57 nd SUVmax, respectively) with those of (18)F fluorodeoxyglucose (FDG) across a variety of organs.
59 ) and CT (hereafter, PET/CT) with 6.9 mCi of fluorodeoxyglucose (FDG) and magnetic resonance (MR) ima
60 ted tomography (PET/CT) imaging with [(18)F]-fluorodeoxyglucose (FDG) can monitor monkeypox disease p
62 ission tomography (PET) studies with [(18)F]-fluorodeoxyglucose (FDG) during sleep and anesthesia, th
63 omography and magnetic resonance using (18)F-fluorodeoxyglucose (FDG) for glucose uptake was performe
64 and its implications for fluorine 18 ((18)F) fluorodeoxyglucose (FDG) imaging of atherosclerosis.
65 C11 Pittsburgh compound B (amyloid), and F18 fluorodeoxyglucose (FDG) in 90 clinically normal elderly
66 positron emission tomography (PET) and (18)F-fluorodeoxyglucose (FDG) in sixteen healthy controls and
67 pecific insulin-mediated fluorine 18 ((18)F) fluorodeoxyglucose (FDG) influx rates, tissue depots, an
68 nancy, bone marrow activity from fluorine 18-fluorodeoxyglucose (FDG) PET may be informative for clin
69 mpairment, or neither at fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET of the brain and compare it
75 aging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by Q
77 In this retrospective study, 110 whole-body fluorodeoxyglucose (FDG) PET/CT studies acquired in 107
78 FPPRGD2 PET/computed tomography (CT), (18)F fluorodeoxyglucose (FDG) PET/CT, and brain magnetic reso
79 on between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
80 tabolism, exemplified by fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
81 econd deep-inspiration breath hold (DIBH) in fluorodeoxyglucose (FDG) positron emission tomography (P
82 o assess whether dynamic fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
83 ssess the diagnostic accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
85 abolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (P
87 aracteristics of interim fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
88 ed patterns of hypometabolism on fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
89 rast of melanin in comparison to fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
90 omputed tomography (CT), fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
91 abdomen, and pelvis; and fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
92 (11)C]Pittsburgh compound B (PIB) and [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (P
94 ic nodal status with use of four fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
99 interpretative criteria (IC) for Fluorine-18 fluorodeoxyglucose (FDG) Positron Emission Tomography -
100 as total glycolytic activity (TGA) on [18]F-fluorodeoxyglucose (FDG) positron emission tomography-co
101 iated with increased glycolysis and that 18F-fluorodeoxyglucose (FDG) positron emission tomography-co
102 sburgh compound B (PIB; amyloid) and [(18) F]fluorodeoxyglucose (FDG) positron emission tomography.
105 , (11)C-deuterium-L-deprenyl (DED) and (18)F-fluorodeoxyglucose (FDG) respectively in presymptomatic
106 ase, who were referred for PET, using [(18)F]fluorodeoxyglucose (FDG) to assess for inflammation and
107 mography (PET) scanning and the tracer (18)F-fluorodeoxyglucose (FDG) to document regional metabolic
108 in lymphoma lesions and to compare these to fluorodeoxyglucose (FDG) uptake and biologic markers of
110 nce, the radiolabeled glucose analogue, [18F]fluorodeoxyglucose (FDG), is routinely used in positron
111 etermine the clinical significance of [(18)F]fluorodeoxyglucose (FDG)-avid lesions in patients with l
113 nce of arterial inflammation in the aorta by fluorodeoxyglucose (FDG)-PET, and LDL-cholesterol concen
114 of having abdominal or thoracic fluorine 18 fluorodeoxyglucose (FDG)-positive lesions underwent clin
116 s, we investigated whether noninvasive (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (P
118 sured with positron emission tomography with fluorodeoxyglucose (FDG-PET) is of primary importance in
119 rrelated with lung inflammation (lung [(18)F]fluorodeoxyglucose [FDG] avidity) measured by positron e
120 [(11)C]3-O-methylglucose [3-OMG], and [(18)F]fluorodeoxyglucose [FDG]) to quantify, respectively, ske
121 ts with HCC underwent PET imaging with (18)F-fluorodeoxyglucose, followed by (18)F-fluorocholine trac
122 ell as PET studies using fluorine 18 ((18)F) fluorodeoxyglucose, gallium 68 ((68)Ga) tetraazacyclodod
124 fluoride (calcification activity) and (18)F-Fluorodeoxyglucose (inflammation activity) positron emis
127 ) C-Pittsburgh compound B (n = 306) and (18) fluorodeoxyglucose (n = 305) positron emission tomograph
132 thods Between 2010 and 2013, 219 fluorine 18 fluorodeoxyglucose PET examinations were performed in 11
134 retrospective study, the pretreatment (18)F fluorodeoxyglucose PET images in 101 patients treated wi
135 s for controlling the quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to ensure the
136 ometabolism typically seen on interictal 18F-fluorodeoxyglucose PET imaging in patients with focal ep
137 tion of functional (high density EEG and 18F-fluorodeoxyglucose PET imaging) and structural (diffusio
140 model that includes pretreatment fluorine 18-fluorodeoxyglucose PET texture features from the primary
141 tion, because blankets are commonly used for fluorodeoxyglucose PET to maintain a normal body tempera
142 calization and classification of fluorine 18-fluorodeoxyglucose PET uptake patterns in foci suspiciou
143 set of multimodality images (CT, fluorine 18 fluorodeoxyglucose PET, and T1-weighted MRI) from 51 pat
144 ve in (18)F-fluorocholine PET, but not (18)F-fluorodeoxyglucose PET, and they overexpressed the choli
145 ET, posterior cortical metabolism with (18)F-fluorodeoxyglucose PET, hippocampal volume (age and sex
146 s of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measur
149 or size and central pelvic spread) and torso fluorodeoxyglucose PET/CT (to assess lymphadenopathy and
150 ons were evaluated at (18)F- FDG fluorine 18 fluorodeoxyglucose PET/CT and (18)F- FPPRGD2 2-fluoropro
151 re the diagnostic performance of fluorine 18 fluorodeoxyglucose PET/CT and diffusion-weighted (DW) MR
152 l malignancies underwent two FDG fluorine 18 fluorodeoxyglucose PET/CT examinations within 1 week.
154 DS AND We performed (18)F-fluoride and (18)F-fluorodeoxyglucose PET/CT in 26 patients after recent tr
155 omparable or superior to that of fluorine 18 fluorodeoxyglucose PET/CT in the differentiation of mali
156 s recommended in multicenter FDG fluorine 18 fluorodeoxyglucose PET/CT studies on the basis of a high
157 s-sectional imaging (CT, MRI, or fluorine 18 fluorodeoxyglucose PET/CT) between April 2010 and Decemb
158 s, they were also evaluated with fluorine 18 fluorodeoxyglucose PET/CT, with imaging findings reviewe
159 uspected of having lung cancer who underwent fluorodeoxyglucose PET/MRI between October 2018 and Apri
160 howed significant agreement with fluorine 18 fluorodeoxyglucose PET/MRI for treatment response assess
161 d (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose ) PET/CT examinations were performed
163 uid (CSF); and one or more of PET with (18)F-fluorodeoxyglucose, PET with amyloid tracers, and MRI.
167 ogical, magnetic resonance imaging and (18)F-fluorodeoxyglucose positon emission tomography data were
168 zole positron emission tomographic and (18)F-fluorodeoxyglucose positron emission tomographic imaging
169 gle-photon emission computed tomography, and fluorodeoxyglucose positron emission tomographic scans r
170 igh risk for atherosclerosis underwent (18)F-fluorodeoxyglucose positron emission tomographic/compute
171 patterns, the extent of resection of (18) F-fluorodeoxyglucose positron emission tomography ((18) FD
172 process that is observed clinically by (18)F-fluorodeoxyglucose positron emission tomography ((18)F-F
174 ting brain metabolism measurement using (18) fluorodeoxyglucose positron emission tomography (31 pati
175 on can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]
176 and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]
177 hildhood temperament and high-resolution (18)fluorodeoxyglucose positron emission tomography (FDG-PET
178 group clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET
179 dy had undergone magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (FDG-PET
180 zed by progressive hypometabolism on [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET
181 application of functional imaging with (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET
182 in large cell lymphoma, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET
183 y means of CT-based criteria with respect to fluorodeoxyglucose positron emission tomography (FDG-PET
184 All participants underwent brain [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET
187 the impact of an end-of-treatment (EOT) 18F-fluorodeoxyglucose positron emission tomography (PET) sc
188 rd improved outcomes at 1 year using an F-18-fluorodeoxyglucose positron emission tomography (PET)-as
189 were measured with (11)C-palmitate and (18)F-fluorodeoxyglucose positron emission tomography (PET)/co
190 ification software application to hybrid 18F-fluorodeoxyglucose positron emission tomography (PET)/co
191 oth computed tomography (CT) and fluorine-18 fluorodeoxyglucose positron emission tomography (PET)/CT
192 of regional brain metabolism (resting state fluorodeoxyglucose positron emission tomography [FDG-PET
194 ure cortical thickness alone; (iii) abnormal fluorodeoxyglucose positron emission tomography alone; (
195 y assess the diagnostic accuracy of Fluor-18-fluorodeoxyglucose positron emission tomography and comp
197 unctional consequences of cue exposure using fluorodeoxyglucose positron emission tomography and to r
198 imaging, diffusion tensor imaging and (18)F-fluorodeoxyglucose positron emission tomography at both
199 of Health (NIH) participants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed
201 ase signature cortical thickness or abnormal fluorodeoxyglucose positron emission tomography definiti
202 An additional 20 participants underwent fluorodeoxyglucose positron emission tomography followin
203 underwent metabolic brain imaging with (18)F-fluorodeoxyglucose positron emission tomography for atyp
205 lation with inflammation-induced fatigue and fluorodeoxyglucose positron emission tomography imaging,
206 (cross-sectionally); and hippocampal volume, fluorodeoxyglucose positron emission tomography results
207 e gold standard for diagnosis of RS; a (18)F-fluorodeoxyglucose positron emission tomography scan can
208 ent a combination of laboratory testing, 18F-fluorodeoxyglucose positron emission tomography scan, ca
211 rmacokinetic analysis and activity on [(18)F]fluorodeoxyglucose positron emission tomography scans di
212 11195, (11)C-Pittsburgh compound B and (18)F-fluorodeoxyglucose positron emission tomography scans fo
213 lysis of cross-sectional resting-state (18)F-fluorodeoxyglucose positron emission tomography scans fr
218 egional glucose metabolism measured by (18)F-fluorodeoxyglucose positron emission tomography with and
222 primate and functional neuroimaging ([(18)F]fluorodeoxyglucose positron emission tomography) with a
223 t standardized clinical assessment, brain 18-fluorodeoxyglucose positron emission tomography, electro
224 disease burden obtained from baseline (18)F-fluorodeoxyglucose positron emission tomography-computed
226 , or routine follow-up with biannual [(18)F]-fluorodeoxyglucose positron emission tomography-computed
227 patients and healthy controls underwent (18)fluorodeoxyglucose positron emission tomography-computed
228 ion glycolysis (WB-TLG) measured with [(18)F]fluorodeoxyglucose positron emission tomography-computed
234 We included individuals who underwent (18)F-fluorodeoxyglucose positron emission tomography/computed
235 glucose uptake in BAT, as assessed by [(18)F]fluorodeoxyglucose positron emission tomography/computed
237 ng relied on the use of clinical fluorine 18 fluorodeoxyglucose positron emission tomography/computed
238 asive multimodality imaging) study underwent fluorodeoxyglucose positron emission tomography/computed
239 ely determine the prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography/computed
240 report two cases of SOS investigated by 18F-fluorodeoxyglucose positron emission tomography/computed
242 rected for lean body mass (SULmax) on [(18)F]fluorodeoxyglucose positron emission tomography/computed
245 as to evaluate the diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed
246 espectively 80%, 91%, 80%, and 91% for (18)F-fluorodeoxyglucose positron emission tomography/CT and 6
248 n of CIED infection who underwent both (18)F-fluorodeoxyglucose positron emission tomography/CT and w
249 rmal adjusted hippocampal volume or abnormal fluorodeoxyglucose positron emission tomography; and (v)
251 limits ventricular remodeling as assessed by fluorodeoxyglucose-positron emission tomographic imaging
254 lesions confirmed the same disease, and [18F]fluorodeoxyglucose-positron emission tomography demonstr
255 lso highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging
259 taiodobenzylguanidine (MIBG) scans or [(18)F]fluorodeoxyglucose-positron emission tomography scans if
263 with severe carotid stenosis underwent (18)F-fluorodeoxyglucose-positron emission tomography/computed
264 This study aimed to assess the role of (18)F-fluorodeoxyglucose-positron emission tomography/computed
265 ntation and reporting of surveillance [(18)F]fluorodeoxyglucose-positron emission tomography/computed
268 e-body magnetic resonance imaging, and (18)F-fluorodeoxyglucose-positron emission tomography/computed
269 lume (TMTV) measured at baseline with [(18)F]fluorodeoxyglucose/positron emission tomography-computed
272 used positron emission tomography and (18)F-fluorodeoxyglucose to measure brain glucose metabolism (
273 itron emission tomography was conducted with fluorodeoxyglucose to measure cerebral metabolism and Pi
274 anned with [(15)O]-labeled water and [(18)F]-fluorodeoxyglucose, to map regional cerebral blood flow
275 index, metabolic syndrome, and aortic (18)F-fluorodeoxyglucose uptake (a measure of arterial inflamm
277 on was most apparent in tumors with high (18)fluorodeoxyglucose uptake and aggressive oncological beh
278 sterol-modified agomiR-199a inhibits [(18)F]-fluorodeoxyglucose uptake and attenuates tumor growth in
280 t controlling for SVD, subtle differences in fluorodeoxyglucose uptake between early-onset AD and lat
284 mediastinal adenopathy with increased [(18)F]fluorodeoxyglucose uptake on PET and scattered diffuse 1
285 gadolinium enhancement on MRI, increased (18)fluorodeoxyglucose uptake on positron emission tomograph
286 including magnetic resonance imaging, (18)F-fluorodeoxyglucose uptake positron emission tomography/c
287 ng our analysis to regions with high [(18)F]-fluorodeoxyglucose uptake provided the best combination
288 al lung inflammation assessed by specific [F]fluorodeoxyglucose uptake rate (median [25-75% percentil
292 21 of 23 (91%) patients, whereas abnormal 18-fluorodeoxyglucose uptake was found in 15 of 23 (65%) ca
294 ection, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximum standardiz
295 inutes, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximum standardiz
296 iated with the local calcium score and (18)F-Fluorodeoxyglucose uptake, as well as female sex and ren
297 ection of rapid inhibitory effects on [(18)F]fluorodeoxyglucose uptake, assessed through noninvasive